BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 24636599)

  • 1. The concept behind sugammadex.
    Epemolu O; Bom A
    Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.
    Cammu G; De Kam PJ; Demeyer I; Decoopman M; Peeters PA; Smeets JM; Foubert L
    Br J Anaesth; 2008 Mar; 100(3):373-9. PubMed ID: 18238834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sugammadex, a novel drug for neuromuscular blockade reversal].
    Fernández Meré LA; Alvarez-Blanco M
    Rev Esp Anestesiol Reanim; 2010 Feb; 57(2):95-102. PubMed ID: 20337001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.
    Schaller SJ; Lewald H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1097-108. PubMed ID: 27463265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of sugammadex (Org 25969) in reversing moderate neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
    Takeda J; Iwasaki H; Yamakage M; Ozaki M; Kawamata M; Hatano Y; Yorozuya T; Miyakawa H; Kanmura Y
    Masui; 2014 Oct; 63(10):1075-82. PubMed ID: 25693332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients].
    Takeda J; Iwasaki H; Otagiri T; Katoh T; Shingu K; Obara H; Nakatsuka H; Tomiyama Y; Kasaba T
    Masui; 2014 Oct; 63(10):1083-8. PubMed ID: 25693333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacology of sugammadex.
    Bom A; Hope F; Rutherford S; Thomson K
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.
    Suy K; Morias K; Cammu G; Hans P; van Duijnhoven WG; Heeringa M; Demeyer I
    Anesthesiology; 2007 Feb; 106(2):283-8. PubMed ID: 17264722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C; Bergner UA; Pühringer FK
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
    Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
    Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
    Mosing M; Auer U; West E; Jones RS; Hunter JM
    Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications and clinical use of sugammadex].
    Debaene B; Meistelman C
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S57-63. PubMed ID: 19887279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Sugammadex in Patients With Obesity: A Pooled Analysis.
    Monk TG; Rietbergen H; Woo T; Fennema H
    Am J Ther; 2017; 24(5):e507-e516. PubMed ID: 26398716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on sugammadex sodium.
    Welliver M; Cheek D
    AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    Brueckmann B; Sasaki N; Grobara P; Li MK; Woo T; de Bie J; Maktabi M; Lee J; Kwo J; Pino R; Sabouri AS; McGovern F; Staehr-Rye AK; Eikermann M
    Br J Anaesth; 2015 Nov; 115(5):743-51. PubMed ID: 25935840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.